{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-25-059900","form_type":"8-K","ticker":"BCLI","cik":"0001137883","company_name":"BRAINSTORM CELL THERAPEUTICS INC.","filed_at":"2025-06-16T23:59:59+00:00","discovered_at":"2026-05-14T18:02:47.632115+00:00","generated_at":"2026-05-19T06:05:39.204100+00:00","sec_items":["8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"BrainStorm reports 90% of ALS patients in NurOwn EAP survived over 5 years","bullets":["9 of 10 NurOwn EAP participants survived >5 years from symptom onset vs. ~10% typical survival in ALS.","Median survival in small cohort was 6.8 years; only death was elective euthanasia.","Company says data strengthens rationale for Phase 3b trial of NurOwn in ALS under FDA SPA.","CEO and CMO highlighted clinically meaningful observation in press release."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-25-059900","json":"https://secwatch.observer/filing/0001104659-25-059900.json","markdown":"https://secwatch.observer/filing/0001104659-25-059900.md","text":"https://secwatch.observer/filing/0001104659-25-059900.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1137883/000110465925059900/0001104659-25-059900-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1137883/000110465925059900/tm2518123d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-19T06:05:39.204100+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}